• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

短期肺癌生存的危险因素。

Risk Factors for Short-Term Lung Cancer Survival.

作者信息

Caballero-Vázquez Alberto, Romero-Béjar José Luis, Albendín-García Luis, Suleiman-Martos Nora, Gómez-Urquiza José Luis, Cañadas Gustavo Raúl, Cañadas-De la Fuente Guillermo Arturo

机构信息

Diagnostic Lung Cancer Unit, Broncopleural Techniques and Interventional Pulmonology Departament, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain.

Department of Statistics and Operational Research, University of Granada, Avda Fuentenueva, E-18071 Granada, Spain.

出版信息

J Clin Med. 2021 Feb 1;10(3):519. doi: 10.3390/jcm10030519.

DOI:10.3390/jcm10030519
PMID:33535673
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7867142/
Abstract

BACKGROUND

Lung cancer is typically diagnosed in an advanced phase of its natural history. Explanatory models based on epidemiological and clinical variables provide an approximation of patient survival less than one year using information extracted from the case history only, whereas models involving therapeutic variables must confirm that any treatment applied is worse than surgery in survival terms. Models for classifying less than one year survival for patients diagnosed with lung cancer which are able to identify risk factors and quantify their effect for prognosis are analyzed.

METHOD

Two stepwise binary logistic regression models, based on a retrospective study of 521 cases of patients diagnosed with lung cancer in the Interventional Pneumology Unit at the Hospital "Virgen de las Nieves", Granada, Spain.

RESULTS

The first model included variables age, history of pulmonary neoplasm, tumor location, dyspnea, dysphonia, and chest pain. The independent risk factors age greater than 70 years, a peripheral location, dyspnea and dysphonia were significant. For the second model, treatments were also significant.

CONCLUSIONS

Age, history of pulmonary neoplasm, tumor location, dyspnea, dysphonia, and chest pain are predictors for survival in patients diagnosed with lung cancer at the time of diagnosis. The treatment applied is significant for classifying less than one year survival time which confirms that any treatment is markedly inferior to surgery in terms of survival. This allows to consider applications of more or less aggressive treatments, anticipation of palliative cares or comfort measures, inclusion in clinical trials, etc.

摘要

背景

肺癌通常在其自然病程的晚期被诊断出来。基于流行病学和临床变量的解释模型仅使用从病历中提取的信息,对患者生存期不到一年的情况提供了一个近似估计,而涉及治疗变量的模型必须确认所应用的任何治疗在生存期方面都比手术差。分析了用于对肺癌患者生存期不到一年进行分类的模型,这些模型能够识别危险因素并量化其对预后的影响。

方法

基于对西班牙格拉纳达“拉斯涅韦斯圣母医院”介入肺病科521例肺癌确诊患者的回顾性研究,建立了两个逐步二元逻辑回归模型。

结果

第一个模型包括年龄、肺部肿瘤病史、肿瘤位置、呼吸困难、声音嘶哑和胸痛等变量。独立危险因素为年龄大于70岁、外周位置、呼吸困难和声音嘶哑。对于第二个模型,治疗方法也具有显著性。

结论

年龄、肺部肿瘤病史、肿瘤位置、呼吸困难、声音嘶哑和胸痛是肺癌确诊患者诊断时生存期的预测因素。所应用的治疗方法对于分类生存期不到一年具有显著性,这证实了任何治疗在生存期方面明显不如手术。这使得可以考虑应用或多或少积极的治疗方法、预期姑息治疗或舒适措施、纳入临床试验等。

相似文献

1
Risk Factors for Short-Term Lung Cancer Survival.短期肺癌生存的危险因素。
J Clin Med. 2021 Feb 1;10(3):519. doi: 10.3390/jcm10030519.
2
Identifying risk factors for imminent death in cancer patients with acute dyspnea.识别急性呼吸困难癌症患者即将死亡的风险因素。
J Pain Symptom Manage. 2000 Nov;20(5):318-25. doi: 10.1016/s0885-3924(00)00193-7.
3
Physical Deconditioning in Lung Cancer Patients Who Underwent Lung Resection Surgery in Spain: A Prospective Observational Study.西班牙接受肺切除手术的肺癌患者的身体机能减退:一项前瞻性观察研究。
Cancers (Basel). 2024 Aug 8;16(16):2790. doi: 10.3390/cancers16162790.
4
Predictors of dyspnea in patients with advanced cancer.晚期癌症患者呼吸困难的预测因素。
Ann Palliat Med. 2018 Oct;7(4):427-436. doi: 10.21037/apm.2018.06.09. Epub 2018 Jul 13.
5
Screening for patients with non-small cell lung cancer who could survive long term chemotherapy.筛选可能从长期化疗中存活的非小细胞肺癌患者。
Asian Pac J Cancer Prev. 2015;16(2):647-52. doi: 10.7314/apjcp.2015.16.2.647.
6
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.意大利癌症数据——2015年报告:意大利罕见癌症的负担
Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035.
7
Epidemiological Evolution of Lung Cancer in the South of Spain from 1990 to 2010.1990年至2010年西班牙南部肺癌的流行病学演变
Zhongguo Fei Ai Za Zhi. 2018 Jan 20;21(1):32-36. doi: 10.3779/j.issn.1009-3419.2018.01.05.
8
Development and Validation of a Prognostic Survival Model With Patient-Reported Outcomes for Patients With Cancer.开发和验证一种基于患者报告结局的癌症患者预后生存模型。
JAMA Netw Open. 2020 Apr 1;3(4):e201768. doi: 10.1001/jamanetworkopen.2020.1768.
9
What is special about patients with lung cancer and pulmonary metastases in palliative care? Results from a nationwide survey.在姑息治疗中,肺癌和肺转移患者有哪些特点?一项全国性调查的结果。
J Palliat Med. 2012 Sep;15(9):971-7. doi: 10.1089/jpm.2011.0434. Epub 2012 Jun 25.
10
Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience.小细胞肺癌的长期生存与毒性。西南肿瘤协作组的扩展经验。
Chest. 1991 Jun;99(6):1425-32. doi: 10.1378/chest.99.6.1425.

引用本文的文献

1
The Role of Inhaled Chitosan-Based Nanoparticles in Lung Cancer Therapy.吸入性壳聚糖基纳米颗粒在肺癌治疗中的作用
Pharmaceutics. 2024 Jul 23;16(8):969. doi: 10.3390/pharmaceutics16080969.
2
Predicting the behavioral intentions of hospice and palliative care providers from real-world data using supervised learning: A cross-sectional survey study.利用监督学习从真实世界数据预测临终关怀和姑息治疗提供者的行为意向:一项横断面调查研究。
Front Public Health. 2022 Sep 30;10:927874. doi: 10.3389/fpubh.2022.927874. eCollection 2022.

本文引用的文献

1
Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases.新发非小细胞肺癌脑转移患者的神经症状负担影响生存预后。
Cancer. 2020 Oct 1;126(19):4341-4352. doi: 10.1002/cncr.33085. Epub 2020 Jul 17.
2
Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer.免疫疗法在晚期非小细胞肺癌中的快速应用的真实世界进展、治疗和生存结果。
Cancer. 2019 Nov 15;125(22):4019-4032. doi: 10.1002/cncr.32383. Epub 2019 Aug 5.
3
Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).吉非替尼治疗选择的晚期非小细胞肺癌患者的长期安全性和生存:来自美国 IRESSA 临床准入计划(ICAP)的结果。
Cancer. 2018 Jun 1;124(11):2407-2414. doi: 10.1002/cncr.31313. Epub 2018 Mar 26.
4
Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity.高合并症非小细胞肺癌患者的治疗及预后
Cancer Manag Res. 2018 Jan 24;10:167-175. doi: 10.2147/CMAR.S151935. eCollection 2018.
5
Post-diagnosis weight loss as a prognostic factor in non-small cell lung cancer.诊断后体重减轻作为非小细胞肺癌的预后因素。
J Cachexia Sarcopenia Muscle. 2018 Feb;9(1):86-92. doi: 10.1002/jcsm.12253. Epub 2017 Dec 4.
6
Lung cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.2001 - 2009年美国按种族和分期划分的肺癌生存率:CONCORD - 2研究结果
Cancer. 2017 Dec 15;123 Suppl 24(Suppl 24):5079-5099. doi: 10.1002/cncr.31029.
7
Progress and prospects of early detection in lung cancer.肺癌早期检测的进展与展望。
Open Biol. 2017 Sep;7(9). doi: 10.1098/rsob.170070.
8
Interventional Analgesic Management of Lung Cancer Pain.肺癌疼痛的介入性镇痛管理
Front Oncol. 2017 Feb 14;7:17. doi: 10.3389/fonc.2017.00017. eCollection 2017.
9
Dyspnea in lung cancer patients: a systematic review.肺癌患者的呼吸困难:一项系统评价
Lung Cancer (Auckl). 2010 Nov 22;1:141-150. doi: 10.2147/LCTT.S14426. eCollection 2010.
10
Symptomatic Treatment of Cough Among Adult Patients With Lung Cancer: CHEST Guideline and Expert Panel Report.成年肺癌患者咳嗽的对症治疗:CHEST指南与专家小组报告
Chest. 2017 Apr;151(4):861-874. doi: 10.1016/j.chest.2016.12.028. Epub 2017 Jan 17.